Theragen Bio Analyzes Largest Covid-19 Patient Data in Korea

SEOUL, KOREA, July 28, 2020 - (ACN Newswire) - Theragen Bio is conducting
joint research on developing a new coronavirus (COVID-19) genomic big data in
collaboration with the Korea Research Institute of Chemical Technology
(KRICT), Kyungpook National University Hospital, and the Daegu Metropolitan

The study will analyze the full genome of each patient and the SARS-CoV-2
virus using samples from approximately 1,000 COVID-19 patients in Daegu and
Gyeongsangbuk-do provence, the largest coronavirus genomic analysis to be
conducted in Korea.

Through this study, Theragen hopes to identify the infection correlation
between patient genome and the SARS-CoV-2 virus genome, and apply it to future
vaccine development. Theragen identified the genetic correlation while
establishing big data for SARS-CoV-2 mutations.

Based on its own Next Generation Sequencing (NGS), Theragen's
ultra-sensitive Covid-19 RNA analysis system can decode over 30,000
full-legnth RNA sequences per virus. The SARS-CoV-2 virus mutates frequently,
however the system can check RNA mutation, replication, and generation.

In addition, the evolution of the SARS-CoV-2 virus can be traced back to
understand the transmission mechanisms between humans and predict clinical
patterns, identify high-risk groups, improve the efficiency of PCR-based
diagnosis, and secure evidence for prevention and prevention strategies.

Hwang Tae-soon, the CEO of Theragen Bio, explains, "This research is the
first attempt to analyze whether there are differences in infection
susceptibility depending on the genetic predisposition of infected patients as
well as mutations and the evolution of the virus. It will be applicable to
various infectious diseases in the future, as well as clinical prediction and
vaccine development."

In April, Theragen Bio collaborated on research for a high-resolution genetic
map of SARS-CoV-2, developed by Narry Kim, head of the RNA research group at
the Institute for Basic Science (IBS), Hyeshik Chang, a professor at the
Department of Biological Sciences, Seoul National University, in collaboration
with Korea National Institute of Health (KNIH) within Korea Centers for
Disease Control & Prevention (KCDC).

This study found the location of the coronavirus gene and RNA variations, to
identify the transcriptome composition and the proliferation principles of the
virus. In May, Theragen Bio traced the Seoul Itaewon cluster infections by
sequencing the genomic materials and RNA transcriptomes and found that this
SARS-CoV-2 variation originated in the U.S.

Theragen Bio, formerly the genome division of Theragen Etex (Kosdaq:066700),
was spun off in March, 2020 to actively pursue customized pharmaceutical &
new drug development and other projects featuring genomic technology. For
further iniformation, please visit